Compare KTB & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTB | ARQT |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.5B |
| IPO Year | 2018 | 2020 |
| Metric | KTB | ARQT |
|---|---|---|
| Price | $66.62 | $23.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $99.67 | $34.00 |
| AVG Volume (30 Days) | 687.4K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 2.82 | 0.03 |
| Revenue | ★ $2,097,839,000.00 | $376,072,000.00 |
| Revenue This Year | $10.39 | $34.85 |
| Revenue Next Year | $3.91 | $29.39 |
| P/E Ratio | ★ $23.82 | $794.67 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $56.19 | $16.62 |
| 52 Week High | $88.96 | $31.77 |
| Indicator | KTB | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 27.91 | 37.18 |
| Support Level | $66.20 | $22.73 |
| Resistance Level | $72.18 | $23.46 |
| Average True Range (ATR) | 2.78 | 0.79 |
| MACD | -1.15 | -0.06 |
| Stochastic Oscillator | 5.67 | 9.76 |
Kontoor Brands Inc is a lifestyle apparel company. It designs, manufactures, procures, sells, and licenses apparel, footwear, and accessories, mainly under the brand names Wrangler, Lee, Helly Hansen, and a few other brands. The company also licenses the use of its brands in certain regions. Its products are sold through wholesale and direct-to-consumer channels in the United States (its key revenue-generating market) and internationally, mainly in Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Non-U.S. Americas regions. The company's three reportable segments are Wrangler, Lee, and Helly Hansen. The majority of its revenue is generated from the Wrangler segment, which offers denim, apparel, footwear, and accessories through Wrangler and various sub-brands.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.